Key points from article :
Immorta Bio is a new company focused on treating aging and age-related diseases using stem cell-based therapies. It was formed by the Venvalo Group and led by Dr. Boris Reznik, who believes that curing diseases of aging means directly addressing aging itself. The company is developing three key types of personalized stem cells: PRCs, which can become any type of cell; pMSCs, which are repair cells tailored to the patient; and PPCs, which may replace damaged tissue with younger, functioning tissue.
Their early efforts will target serious conditions like heart failure, liver failure, and multiple organ failure. These conditions affect many older people and often have limited treatment options. While they work toward FDA approval, they plan to offer cell banking for healthy adults and patients. This means your own cells can be stored and used later when needed.
Dr. Thomas Ichim, the company’s CSO, highlighted that their goal is to provide these personalized cells as a medical option once needed. The idea is to have the cells ready before illness strikes, reducing recovery time and increasing treatment success.
The work is being carried out in the U.S., though the exact lab or clinical site wasn’t named. The research is not yet published in a specific journal, as this is an early-stage company announcement.
The parent company, Venvalo Group, supports tech-based startups and helps them grow in value using its own business strategies. Their main aim is to help early-stage biotech companies like Immorta Bio reach real-world impact.
